查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529796

多核苷酸注射剂的全球市场：市场规模、份额和趋势分析 - 按应用、最终用途、地区和细分市场预测，2024-2030 年

Polynucleotides Injectable Market Size, Share & Trends Analysis Report By Application (Eyes, Lips, Forehead, Jawline & Cheekbones), By End-use (MedSpas, Aesthetic & Cosmetic Centers), By Region, and Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

预计2023年全球多核苷酸注射市场规模将达1.115亿美元，2024年至2030年复合年增长率为14.9%。

生物技术的技术进步主要推动了市场的发展，而对活肤、个人化医疗以及研发 (R&D) 投资的不断增长的需求也推动了市场的发展。根据 PMTA Journal 2024 年 3 月发表的报导，多核苷酸注射剂因其对皮肤、头髮和其他组织的有益作用而被用于美容医学，正如这篇综合评论中所讨论的那样，它开始受到关注。

对先进活肤治疗的需求不断增长是多核苷酸注射市场的主要驱动因素。随着人们寻求更有效的解决方案来解决细纹、皱纹和皮肤下垂等老化征兆，对多核苷酸等新型注射疗法的兴趣正在飙升。例如，最近发表在《皮肤病治疗》杂誌上的一项研究发现，多核苷酸注射可以改善 30 多岁和 40 多岁患者的肤色、细纹、皮肤弹性和水合作用。

对个人化医疗的日益关注也有助于市场成长。随着医疗保健提供者和患者越来越多地寻求客製化的皮肤再生方法，多核苷酸刺激人体天然胶原蛋白产生和细胞再生的能力使其成为受欢迎的选择。这一趋势在个人化美容护理需求不断增长中尤为明显，预计市场将继续扩大。

最后，数位成像和自动注射系统等创新技术的整合进一步推动了多核苷酸注射剂市场的发展。这些进步提高了可注射多核苷酸的准确性、一致性和安全性，使其对医疗保健提供者和患者更具吸引力。随着美容产业的不断发展，最尖端科技的结合预计仍将是多核苷酸注射市场的关键驱动力。例如，伦敦的 Pulse Light Clinic 将在 2022 年推出 Croma 的 PhilArt，这是一种创新的多核苷酸输液治疗，可显着增加皮肤水合作用，增加弹性，并刺激天然胶原蛋白的产生。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 多核苷酸注射市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 多核苷酸注射市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 多核苷酸注射液市场：应用预估及趋势分析

  • 应用市场占有率，2023/2030
  • 细分仪表板
  • 全球多核苷酸注射市场，按应用前景
  • 市场规模/预测、趋势分析，2018-2030

第五章多核苷酸注射市场：最终用途估计和趋势分析

  • 2023 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 全球多核苷酸注射市场，按最终用途分類的前景
  • 市场规模/预测、趋势分析，2018-2030

第六章 多核苷酸注射市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 市场规模/预测、趋势分析，2018-2030
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • PHARMA RESEARCH
    • BIOPLUS CO., LTD.
    • LG Chem
    • AMEELA
    • Mastelli
    • Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
    • Promoitalia Laboratories
    • Fox Pharma
    • BR Pharm
    • DermFocus
Product Code: GVR-4-68040-361-6

Polynucleotides Injectable Market Trends

The global polynucleotides injectable market size was estimated at USD 111.5 million in 2023 and is projected to grow at a CAGR of 14.9% from 2024 to 2030.Technological advancements in biotechnology primarily drive the market, as do the growing demand for skin rejuvenation, personalized medicine, and investments in research and development (R&D). According to an article published by PMTA Journal in March 2024, polynucleotide injections gained prominence in aesthetic medicine due to their beneficial effects on skin, hair, and other tissues, as explored in this comprehensive review.

The growing demand for advanced skin rejuvenation treatments is a primary driver of the polynucleotides injectable market. As individuals seek more effective solutions to address signs of aging, such as fine lines, wrinkles, and skin laxity, the interest in novel injectable treatments such as polynucleotides has surged. For instance, a recent study published in the journal Dermatologic Therapy found that polynucleotide injections improved skin tone, fine lines, skin elasticity, and hydration in patients in their 30s and 40s.

The increasing focus on personalized medicine also contributed to the growth of the market. As healthcare providers and patients alike seek customized approaches to skin rejuvenation, polynucleotides' ability to stimulate the body's natural collagen production and cellular regeneration made them a popular choice. This trend is particularly evident in the rising demand for personalized aesthetic treatments, which is expected to continue expanding the market.

Finally, integrating innovative technologies, such as digital imaging and automated injection systems, has further propelled the polynucleotides injectables market. These advancements improved polynucleotide injections' precision, consistency, and safety, making them more appealing to healthcare providers and patients. As the aesthetic industry continues to evolve, incorporating cutting-edge technologies is expected to remain a vital driver of the polynucleotide injectable market. For instance, in 2022, Pulse Light Clinic in London is introducing PhilArt by Croma, an innovative polynucleotide injection treatment recognized for significantly enhancing skin hydration, boosting elasticity, and stimulating natural collagen production - a pioneering advancement in skin rejuvenation.

Global Polynucleotides Injectable Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global polynucleotides injectable market report based on application, end-use, and region.

  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Eyes
  • Lips
  • Forehead
  • Jawline & Cheekbones
  • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • MedSpas
  • Aesthetic & Cosmetic Centers
  • Hospitals
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Polynucleotides Injectable Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Growing demand for skin rejuvenation
      • 3.2.1.3. Shifting focus towards regenerative aesthetics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited access to the treatments
  • 3.3. Polynucleotides Injectable Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Polynucleotides Injectable Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Polynucleotides Injectable Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Eyes
      • 4.4.1.1. Eyes market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Lips
      • 4.4.2.1. Lips market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Forehead
      • 4.4.3.1. Forehead market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Jawline & Cheekbones
      • 4.4.4.1. Jawline & Cheekbones market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Polynucleotides Injectable Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Polynucleotides Injectable Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. MedSpas
      • 5.4.1.1. MedSpas market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Aesthetic & Cosmetic Centers
      • 5.4.2.1. Aesthetic & cosmetic centers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hospitals
      • 5.4.3.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Polynucleotides Injectable Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 6.5. North America
    • 6.5.1. North America
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Denmark
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Norway
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. PHARMA RESEARCH
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Others benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. BIOPLUS CO., LTD.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Others benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. LG Chem
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Others benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. AMEELA
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Others benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Mastelli
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Others benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Others benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Promoitalia Laboratories
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Others benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Fox Pharma
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Others benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. BR Pharm
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Others benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. DermFocus
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Others benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 10 Mexico polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 13 Europe polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 15 Germany polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 17 UK polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 19 France polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 21 Italy polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 23 Spain polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 25 Denmark polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 27 Sweden polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 29 Norway polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 33 China polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 34 China polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Japan polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 36 Japan polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 37 India polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 38 India polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 40 South Korea polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Australia polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 42 Australia polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Thailand polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 44 Thailand polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 46 Latin America polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Brazil polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 48 Brazil polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Argentina polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 51 MEA polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 53 MEA polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 54 South Africa polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Africa polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 58 UAE polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Kuwait polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Polynucleotides Injectable market: market outlook
  • Fig. 14 Polynucleotides Injectable competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Polynucleotides Injectable market driver impact
  • Fig. 20 Polynucleotides Injectable market restraint impact
  • Fig. 21 Polynucleotides Injectable market strategic initiatives analysis
  • Fig. 22 Polynucleotides Injectable market: application movement analysis
  • Fig. 23 Polynucleotides Injectable market: application outlook and key takeaways
  • Fig. 24 Eyes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Lips market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Forehead market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Jawline & cheekbones market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Polynucleotides Injectable market: end-use movement analysis
  • Fig. 30 Polynucleotides Injectable market: end-use outlook and key takeaways
  • Fig. 31 MedSpas market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Aesthetic & Cosmetic centers market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Global Polynucleotides Injectable market: Regional movement analysis
  • Fig. 35 Global Polynucleotides Injectable market: Regional outlook and key takeaways
  • Fig. 36 Global Polynucleotides Injectable market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. key country dynamics
  • Fig. 46 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Canada key country dynamics
  • Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico key country dynamics
  • Fig. 50 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 UK key country dynamics
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Germany key country dynamics
  • Fig. 56 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 France key country dynamics
  • Fig. 58 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Italy key country dynamics
  • Fig. 60 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Spain key country dynamics
  • Fig. 62 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Denmark key country dynamics
  • Fig. 64 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Sweden key country dynamics
  • Fig. 66 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Norway key country dynamics
  • Fig. 68 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 China key country dynamics
  • Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan key country dynamics
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 India key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Australia key country dynamics
  • Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea key country dynamics
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Thailand key country dynamics
  • Fig. 82 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Brazil key country dynamics
  • Fig. 86 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Argentina key country dynamics
  • Fig. 88 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 South Africa key country dynamics
  • Fig. 92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Saudi Arabia key country dynamics
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 UAE key country dynamics
  • Fig. 96 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Kuwait key country dynamics
  • Fig. 98 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- Polynucleotides Injectable market